Annual report pursuant to Section 13 and 15(d)

Shareholders' Deficit (Details Textual)

v3.22.1
Shareholders' Deficit (Details Textual) - USD ($)
 1 Months Ended 3 Months Ended 12 Months Ended
Apr. 07, 2021
Mar. 08, 2021
Jan. 07, 2021
Jan. 06, 2021
Dec. 18, 2020
Oct. 09, 2020
Oct. 07, 2020
Oct. 06, 2020
Oct. 02, 2020
Aug. 24, 2020
Jul. 02, 2020
May 08, 2020
Apr. 17, 2020
Apr. 02, 2020
Apr. 01, 2020
Jan. 13, 2020
Dec. 12, 2019
Nov. 19, 2019
Oct. 02, 2019
Aug. 15, 2019
Jul. 29, 2019
Jul. 18, 2019
Jul. 12, 2019
Mar. 14, 2019
Mar. 12, 2019
Mar. 19, 2021
Feb. 01, 2021
Sep. 30, 2020
Aug. 31, 2020
Aug. 20, 2020
Apr. 28, 2020
Feb. 20, 2020
Feb. 18, 2020
Nov. 30, 2019
Nov. 30, 2019
Oct. 31, 2019
Jul. 29, 2019
May 20, 2019
Dec. 27, 2016
Dec. 31, 2020
Dec. 31, 2020
Dec. 31, 2019
Jan. 18, 2021
Dec. 21, 2020
Dec. 14, 2019
Dec. 09, 2019
Sep. 14, 2019
Sep. 06, 2019
Jun. 14, 2019
Shareholders' Deficit (Textual)
Preferred Stock par value $ 0.10 $ 0.10 $ 0.10
Conversion fees $ 2,500
Amortization of debt discount 424,001 $ 160,542
Accrued interest $ 36,244 $ 36,244
Common shares issued for debt conversion, shares 547,945 203,125 37,171,800
Amount of common stock upon conversion $ 12,000 12,000
Shares of common stock upon conversion 295,567
Common shares per share $ 0.012 $ 0.008 $ 0.08 $ 0.04 $ 0.05
Accrued dividends 6,031 $ 6,031
Accrued compensation $ 108,000 $ 318,970
Shares of grant restricted stock award of common shares 500,000 1,275,000 510,000
Value of grant restricted stock award of common shares $ 6,000 $ 10,200 $ 25,500
Stock-based compensation $ 4,603 609,662 1,783,099
Interest expense 751,184 343,078
Issuance of common shares for services, amount 149,475 202,360
Stock-based professional fees $ 10,200 $ 25,500 $ (132,892) $ (355,393)
Non-vested shares 323,373
Common share exercise compensation, shares 16,132,701
Recognized compensation expense $ 7,500
Total unrecognized compensation expense related to unvested common shares $ 446,064 $ 446,064 2,068,368
Weighted average period 1 year
Cash proceeds from investor $ 6,058 $ 117,047
Warrant exercise price reduced $ 0.01 $ 0.01
Fair value of the award amount 12,603
Aggregate principal amount 135,833
Unrecognized compensation expense 110,650
Convert of deferred compensation $ 8,000 $ 16,250
Fair market value of per share $ 0.023 $ 0.055
Sale of common shares, shares 151,456
Exercise of stock options, value 19,185
Reduced accrued compensation $ 90,000
Recorded settlement expense
Increase decrease in accounts payable 139,300 239,605
Increase decrease in accrued expenses 96,022 89,266
Shares issued for deferred compensation, description The Company entered into two one-year advisory board agreements with two individuals for services to be rendered on the Company's medical advisory board. In connection with these advisory board agreements, the Company issued an aggregate of 500,000 restricted common shares of the Company to these advisory board members. These shares vest on April 1, 2021. These shares were valued at $20,000, or $0.04 per common share, based on contemporaneous common share sales by the Company. In connection with this consulting agreement, during the year ended December 31, 2020, accretion of stock-based consulting fees amounted to $15,000 and the remaining stock-based consulting fees of $5,000 shall be accreted over the remaining vesting period.
Conversion of principal balance 152,285
Issued shares of common stock 3,000,000
Accrued dividend payable $ 1,562 4,852
Investor and redeemed 103,200
Redemption penalties $ 12,285
Remaining put premium balance 24,207
Gain on extinguishment 24,207
Conversion Price 450,204
Research and development expense 16,627 31,057
Stock-based professional fees $ 6,000
Vesting period May 01, 2021
Subsequent Event [Member]
Shareholders' Deficit (Textual)
Issued shares of common stock 2,500,000 750,000 1,008,000 100,000 944,767 900,000
Former Chief Executive Officer [Member]
Shareholders' Deficit (Textual)
Common shares per share $ 0.05 $ 0.04 $ 0.05
Convert of deferred compensation $ 80,000 $ 40,000
Convert shares of common stock 2,000,000 800,000
Chief Operating Officer[Member]
Shareholders' Deficit (Textual)
Common shares per share $ 0.04
Convert of deferred compensation $ 80,000
Convert shares of common stock 2,000,000
Fair market value of per share $ 0.04
Employees [Member]
Shareholders' Deficit (Textual)
Common shares per share $ 0.04
Convert of deferred compensation $ 24,000
Convert shares of common stock 600,000
President and Chief Operating Officer [Member]
Shareholders' Deficit (Textual)
Common shares per share 0.05 $ 0.05
Convert of deferred compensation $ 50,000
Convert shares of common stock 1,000,000
Fair market value of per share $ 0.05
Consulting Agreement [Member]
Shareholders' Deficit (Textual)
Common shares per share $ 0.0085 $ 0.17 $ 0.04 $ 0.094
Shares of grant restricted stock award of common shares 9,000,000 485,060 1,250,000 500,000
Value of grant restricted stock award of common shares $ 76,500 $ 82,460 $ 47,000
Stock-based professional fees $ 82,460 $ 47,000 $ 50,000
Employment Agreements [Member]
Shareholders' Deficit (Textual)
Common shares per share $ 0.04
Shares of grant restricted stock award of common shares 200,000
Value of grant restricted stock award of common shares $ 8,000
Patent Expense Reimbursement Agreement [Member]
Shareholders' Deficit (Textual)
Common shares per share $ 0.011
Shares of grant restricted stock award of common shares 25,000
Value of grant restricted stock award of common shares $ 275
Research and development expense $ 275
Marketing Agreement
Shareholders' Deficit (Textual)
Common shares per share $ 0.044
Shares of grant restricted stock award of common shares 350,000
Value of grant restricted stock award of common shares $ 15,400
Stock-based professional fees $ 15,400
Restricted Stock Award Agreements [Member]
Shareholders' Deficit (Textual)
Common shares per share $ 0.04 $ 0.04 $ 0.05 $ 0.05 $ 0.04
Shares of grant restricted stock award of common shares 10,500,000 6,750,000 1,300,000
Value of grant restricted stock award of common shares $ 525,000 $ 270,000 $ 65,000
Percentage of restricted shares 100.00% 100.00% 100.00% 100.00% 100.00%
Employment agreement [Member]
Shareholders' Deficit (Textual)
Common shares per share $ 0.04
Shares of grant restricted stock award of common shares 200,000
Value of grant restricted stock award of common shares $ 8,000
Letter Agreement [Member]
Shareholders' Deficit (Textual)
Stock-based professional fees $ 0 $ 159,700
Exercise price $ 0.18
Risk-free rate 2.43%
Dividend yield 0.00%
Expected term 5 years
Expected volatility 275.00%
Fair value of the award amount $ 159,700
Warrants to purchase shares 1,000,000
Purchase Agreements [member]
Shareholders' Deficit (Textual)
Exercise price $ 0.10 $ 0.10
Fair value of the award amount $ 61,899
Warrants to purchase shares 1,050,000 1,050,000
Purchase Agreements [member] | Subsequent Event [Member]
Shareholders' Deficit (Textual)
Warrants to purchase shares 1,050,000
Cashless exercise of warrants 1,008,000
Investor [Member]
Shareholders' Deficit (Textual)
Common shares per share $ 0.013 $ 0.023 $ 0.04 $ 0.04 $ 0.15
Cash proceeds from investor $ 280,000 $ 161,000 $ 280,000 $ 280,000 $ 300,000
Sale of common shares, shares 21,538,462 7,000,000 7,000,000 7,000,000 2,000,000
Investor [Member]
Shareholders' Deficit (Textual)
Common shares per share $ 0.054 $ 0.054
Cash proceeds from investor $ 100,000 $ 480,000
Sale of common shares, shares 1,851,852 10,750,000
Investor [Member] | Maximum [Member]
Shareholders' Deficit (Textual)
Common shares per share $ 0.05
Investor [Member] | Minimum [Member]
Shareholders' Deficit (Textual)
Common shares per share $ 0.04
Dinosaur Financial Group, LLC [Member] | Letter Agreement [Member]
Shareholders' Deficit (Textual)
Exercise price $ 0.18 $ 0.07 $ 0.05 $ 0.08
Warrants to purchase shares 200,000 200,000 200,000 400,000
Equity Option [Member]
Shareholders' Deficit (Textual)
Exercise price $ 0.31
Exercise of stock options, shares 750,000
Exercise of stock options, value $ 5,000 $ 182,500 $ 182,500
Warrants [Member]
Shareholders' Deficit (Textual)
Exercise price 0.10 $ 0.10
Warrant exercise price reduced $ 0.003 $ 0.003
Warrant purchase, description On March 30, 2020 and on April 23, 2020, in connection with Purchase Agreements with an accredited investor (See Note 6), the Company issued warrants to purchase an aggregate amount up to 288,750 shares of the Company’s common stock (the “Warrants”). The Warrants were exercisable at any time on or after the date of the issuance and entitled this investor to purchase shares of the Company’s common stock for a period of five years from the initial date the warrants become exercisable. Under the terms of the Warrants, the holder was entitled to exercise the Warrants to purchase up to 288,750 shares of the Company'sCompany’s common stock at an initial exercise price of $0.10, subject to adjustment as detailed in the Warrants. In connection with the issuance of the warrants, on the initial measurement date, the relative fair value of the warrants of $14,498 was recorded as a debt discount and an increase in paid-in capital (See Note 6). In September 2020, in connection with the repayment of the debt, these warrants were cancelled.
Preferred Stock [Member]
Shareholders' Deficit (Textual)
Accrued dividend payable $ 2,476
2018 Long-term Incentive Plan [Member]
Shareholders' Deficit (Textual)
Common shares per share $ 0.16
Shares of grant restricted stock award of common shares 200,000
Value of grant restricted stock award of common shares $ 32,000
Aggregate shares of common stock issued without any minimum vesting period 25,000,000
Aggregate number of common stock issued under plan 50,000,000
Incentive stock options 11,445,698 11,445,698
Description of options to acquire common stock The exercise price of options granted under our 2018 Plan must at least be equal to the fair market value of the Company's common stock on the date of grant and the term of an option may not exceed ten years, except that with respect to an incentive stock option granted to any employee who owns more than 10% of the voting power of all classes of the Company's outstanding stock as of the grant date the term must not exceed five years and the exercise price must equal at least 110% of the fair market value on the grant date.
Restricted stock have been issued $ 25,951,070 $ 25,951,070
Percentage of restricted shares 100.00%
Advisory Board Agreement [Member]
Shareholders' Deficit (Textual)
Stock-based professional fees 6,667 $ 25,333
Consulting Agreement [Member]
Shareholders' Deficit (Textual)
Stock-based professional fees 6,500
Consulting Agreement [Member]
Shareholders' Deficit (Textual)
Stock-based professional fees 38,250
Prepaid expenses $ 38,250 $ 38,250
Series A Preferred Stock [Member]
Shareholders' Deficit (Textual)
Shares designated 0 0 800,000
Preferred Stock par value $ 0.10 $ 0.10 $ 0.10 $ 0.10 $ 0.10 $ 0.10
Preferred stock stated value $ 1.00 $ 1.00
Preferred Stock dividend Rate 4.00%
Preferred stock dividend increased 22.00%
Conversion price converted into market price 81.00%
Market price representing at discount rate 19.00%
Debt premium $ 42,553
Debt premium charge to interest expenses $ 31,197
Preferred stock unregistered shares 159,600 159,600 159,600 154,800 154,800
Preferred stock unregistered value $ 133,000 $ 133,000 $ 133,000 $ 129,000 $ 129,000
Cash proceeds 127,000 127,000 120,000
Net of fees 6,000 6,000 9,000
Amortization of debt discount 9,000
Amortization of discount charged to interest expense $ 6,000 $ 6,000 14,333 $ 667
Accrued interest $ 934
Debt premium to paid-in capital. 49,543 49,543
Stated value $ 211,200 $ 211,200
Common shares per share $ 0.833 $ 0.833 $ 0.833 $ 0.833 $ 0.833
Accrued dividends $ 4,224 $ 4,224
Fully redeemed value $ 0 0
Interest expense $ 126,423
Description of options to acquire common stock The Company issued 16,132,701 shares its common stock upon the conversion of 211,200 shares of Series A preferred with a stated redemption value of $211,200 and related accrued dividends payable of $4,224. The conversion price was based on contractual terms of the related Series A preferred shares. Upon conversion, the Company reclassified put premium of $49,543 to paid-in capital.
Series C Preferred Stock [Member]
Shareholders' Deficit (Textual)
Shares designated 100,000 100,000 100,000
Preferred Stock par value $ 0.10 $ 0.10 $ 0.10
Preferred stock stated value $ 100.00 $ 100.00
Preferred stock unregistered value $ 630,000 $ 630,000
Series B Preferred Stock [Member]
Shareholders' Deficit (Textual)
Shares designated 100,000 100,000 100,000 100,000
Preferred Stock par value $ 0.10 $ 0.10 $ 0.10 $ 0.10
Preferred Stock dividend Rate 2.00%
Stated value $ 1,000
Accrued compensation $ 295,000
Series A preferred stock balance $ 429,446 $ 429,446 $ 108,000
Liquidation value $ 426,970 426,970 $ 108,000
Stock-based compensation 1,048,143
Stock option, description The Series B is convertible at the option of a holder or if the closing price of the common stock exceeds 400% of the Conversion Price for a period of twenty consecutive trading days, at the option of the Company. Conversion Price means a price per share of the common stock equal to 100% of the lowest daily volume weighted average price of the common stock during the two years preceding or subsequent two years following the Issuance Date, subject to adjustment as otherwise provided in the Certificate of Designations (the "Conversion Price").
Accrued dividend payable 2,476
Series B Convertible Preferred Stock [Member]
Shareholders' Deficit (Textual)
Settlement of accrued compensation 108 319
Series C Convertible Preferred Stock [Member]
Shareholders' Deficit (Textual)
Preferred stock stated value $ 100 $ 100
Preferred Stock dividend Rate 2.00%
Preferred Stock shares value 630,000 630,000
Purchase of shares 6,300 6,300
Designations established share 100,000
Series C Convertible Preferred Stock [Member] | Subscription Agreements [Member]
Shareholders' Deficit (Textual)
Agreement description The Company entered into subscription agreements with an accredited investor whereby the investor agreed to purchase an aggregate of purchase 7,000 shares of the Company's Series C Convertible Preferred Stock for $700,000, or $100.00 per share (the "Stated Value"), which were used from working capital purposes.
Series C Preferred Stock [Member]
Shareholders' Deficit (Textual)
Preferred Stock par value $ 0.10
Common shares per share $ 100
Series C Preferred Stock [Member]
Shareholders' Deficit (Textual)
Stated value $ 1,330,000 1,330,000
Accrued dividends 6,031 6,031
Series C preferred stock balance 1,336,031 1,336,031
Percentage of redeemed value 150.00%
Non-cash deemed dividend $ 1,525,873 $ 1,525,873